b C efepime, a fourth-generation, extended-spectrum cephalosporin, is often used to treat Enterobacteriaceae infections (1). Concentrations of cefepime above the MIC of the infecting organism for at least 60% to 70% of the dosing interval are recommended to obtain maximal bactericidal effects (2, 3). Doses of 1 to 2 g every 12 h may not achieve adequate concentrations to treat infections when the MIC is 4 g/ml or greater (1, 2). Earlier this year, the Clinical Laboratory and Standards Institute (CLSI) adapted the MIC breakpoints for cefepime against Enterobacteriaceae based upon several studies demonstrating clinical failure for MICs of 4 to 8 g/ml. This MIC range is now considered "susceptible dose dependent" (SDD), suggesting that dosing regimens higher than those needed for isolates with lower drug MICs should be employed (4). These alternative dosing strategies may also be of benefit for infections due to Pseudomonas aeruginosa, which does not currently have an SDD interpretive category.
This evaluation demonstrated that despite significant cefepime exposure in the population, the Enterobacteriaceae and P. aeruginosa cefepime MIC distributions have not demonstrated clinically significant changes. The change in CLSI reporting of Enterobacteriaceae isolates to SDD had a small (3%) impact on previously isolated Enterobacteriaceae bacteria. The future impact of this breakpoint change remains to be seen; however, optimal dosing should be utilized in treating patients infected with organisms within this SDD category.
